Moreover, patients receiving BIIB078 showed a trend toward greater clinical decline and increased levels of NfL in plasma, and further development of BIIB078 was discontinued.
← all excerpts
Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
1
—
—